tradingkey.logo

Milestone Pharmaceuticals Inc

MIST
View Detailed Chart
1.760USD
+0.040+2.33%
Close 02/06, 16:00ETQuotes delayed by 15 min
149.90MMarket Cap
LossP/E TTM

Milestone Pharmaceuticals Inc

1.760
+0.040+2.33%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.33%

5 Days

-7.85%

1 Month

-14.15%

6 Months

+15.03%

Year to Date

-12.87%

1 Year

-19.63%

View Detailed Chart

Key Insights

Milestone Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 140 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.60.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Milestone Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
140 / 392
Overall Ranking
285 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Milestone Pharmaceuticals Inc Highlights

StrengthsRisks
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Fairly Valued
The company’s latest PE is -2.24, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.48M shares, increasing 25.43% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 22.07K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.24.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
6.600
Target Price
+283.72%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Milestone Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Milestone Pharmaceuticals Inc Info

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Ticker SymbolMIST
CompanyMilestone Pharmaceuticals Inc
CEOOliveto (Joseph)
Websitehttps://www.milestonepharma.com
KeyAI